天津医药

天津医药 ›› 2018, Vol. 46 ›› Issue (9): 989-991.doi: 10.11958/20180367

• 临床研究 • 上一篇    下一篇

地佐辛联合右美托咪定降低肠道术后腹腔热灌注化疗不良反应的研究

陈高，张莉，李楚娟   

  1. 湖北省肿瘤医院重症医学科（邮编430079）
  • 收稿日期:2018-03-12 修回日期:2018-05-14 出版日期:2018-09-15 发布日期:2018-10-10
  • 通讯作者: 张莉 E-mail:69504660@qq.com

Effects of dezocine combined with dexmedetomidine on reducing adverse reaction of hyperthermic intraperitoneal chemotherapy after intestinal operation

CHEN Gao, ZHANG Li, LI Chu-juan   

  1. Department of Intensive Care Unit, Hubei Cancer Hospital, Wuhan 430079, China
  • Received:2018-03-12 Revised:2018-05-14 Published:2018-09-15 Online:2018-10-10

PDF (PC)

4084

摘要： 目的 对地佐辛联合右美托咪定在降低肠道术后腹腔热灌注化疗（HIPEC）不良反应中的作用进行研究分析，为临床应用提供参考。方法 80例肠道肿瘤术后接受HIPEC患者，根据不同的镇静镇痛治疗方法分为干预组及常规组，干预组患者在常规镇静镇痛的基础上，HIPEC前10 min给予患者地佐辛5 mg肌内注射、生理盐水48 mL+右美托咪定200 μg以0.3 μg/（kg·h）持续泵入直至HIPEC结束，比较2组患者在HIPEC中不良反应发生的情况。结果2组进行对比发现，干预组患者在HIPEC过程中的心率［（83.34±8.25）次/min vs.（90.11±10.69）次/min］、体温［（37.33±0.42）℃ vs（. 37.95±0.51）℃］均较常规组降低，差异有统计学意义（P＜0.01）；同时干预组的恶心呕吐、疼痛、烦躁等不良反应发生率均低于常规组，差异有统计学意义（P＜0.05）。结论 地佐辛联合右美托咪定用于肠道术后腹腔热灌注化疗能明显降低患者不良反应的发生。

关键词: 右美托咪定；化学疗法, 肿瘤, 局部灌注；地佐辛；腹腔热灌注化疗

Abstract: Objective To observe the effect of dezocine combined with dexmedetomidine on reducing adverse reaction of hyperthermic intraperitoneal chemotherapy (HIPEC) after intestinal operation, and provide reference for clinical application. Methods A total of 80 patients with HIPEC were divided into intervention group and routine group according to different methods of sedation and analgesia. On the basis of routine sedation and analgesia，the 5 mg muscle injection of dizocine was given for patients in intervention group, and normal saline 48 mL+ dexmedetomidine 200 μg were continuously pumped at 0.3 μg/(kg·h) until the end of the HIPEC. The occurrence of adverse reactions in HIPEC was compared between the two groups of patients. Results Results showed that the heart rates [(83.34±8.25) times/min vs. (90.11±10.69) times/min] and body temperature [(37.33±0.42)℃ vs. (37.95±0.51)℃] were significantly lower in the intervention group than those of routine group (P＜0.01). The incidence rates of nausea, vomiting, pain and irritability were significantly lower in the intervention group than those of routine group (P＜0.05). Conclusion Dezocine combined with dexmedetomidine can significantly reduce the incidence of adverse reactions in patients undergoing HIPEC after intestinal surgery.

Key words: dexmedetomidine, chemotherapy, cancer, regional perfusion, dezocine, hyperthermic intraperitoneal chemotherapy